Sandoz

Sandoz

Sandoz is a Durham, North Carolina-based company.

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Sandoz
March 9, 2021
www.prnewswire.com:443
/PRNewswire/ -- Sandoz Inc. today announced the launch of AmLactin® new Rapid Relief Restoring Cream. This new cream is the latest addition in the brand's...
Research and Markets
February 17, 2021
www.prnewswire.com:443
/PRNewswire/ -- The "Analgesics Global Market Report 2020-30: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering. The...
Research and Markets
February 5, 2021
www.prnewswire.com:443
/PRNewswire/ -- The "Filgrastim Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's...
Sandoz
January 28, 2021
www.prnewswire.com:443
/PRNewswire/ -- Sandoz, a global leader in generic and biosimilar medicines, today announced the US launch of generic Icatibant injection pre-filled syringe to...
Alex Keown
June 11, 2020
BioSpace
In the latest legal action, the attorneys general from 46 states, the District of Columbia and four U.S. territories accused the drug makers of conspiring to rig the price of approximately 80 generic drugs between 2009 and 2016
April 20, 2020
WebWire
, , , , • Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease , , • Trial is designed and implemented quickly to address the need for science-based investigation following early preclinical and clinical evidence1,2,3 that hydroxychloroquine may help hospitalized patients with COVID-19 disease , , • Company will also make its hydroxychloroquine intellec...
Ujjval Jauhari
April 2, 2020
@bsindia
Aurobindo was scheduled to acquire the portfolio with an upfront purchase price of $900 million in cash
Reuters Editorial
April 2, 2020
IN
Novartis AG said on Thursday it had scrapped the sale of its U.S. dermatology and generic pill assets to India's Aurobindo Pharma Ltd after failing to get approval from a U.S. regulator.
Reuters Editorial
March 2, 2020
U.S.
Novartis unit Sandoz has agreed to pay $195 million to reach a deferred prosecution agreement aimed at resolving antitrust charges, the Justice Department said on Monday.
Press Trust of India
November 24, 2019
@bsindia
Read more about Aurobindo Pharma aims to become debt-free in the next three years on Business Standard. The company's net debt decreased by $71 million quarter-on-quarter to $522 million at the end of September 2019 against $593 million at the end of June 2019
Reuters Editorial
July 27, 2019
U.S.
Novartis Chief Executive Vas Narasimhan pledged in an interview published on Saturday not to sell the Swiss drugmaker's generics unit Sandoz amid a revamp that has prompted speculation he is preparing to offload the business.
July 4, 2019
WebWire
Sandoz announced the launch of the generic oncology medicine gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK[1], which is recommended by ESMO as first-line treatment[4]. The medicine will become available immediately in 13 countries across Europe on the day the reference medicine loses market exclusivity. Sandoz will continue to expand to other countries through a phased rollout. Generics help e...
Reuters Editorial
May 13, 2019
U.S.
Novartis on Monday said claims of price fixing against its Sandoz generics unit amid a U.S. probe of 20 drugmakers are without merit, with the Swiss company vowing to fight allegations in a lawsuit filed last week.
Reuters Editorial
March 14, 2019
U.S.
Novartis's generics chief is quitting after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.